The 552 million pounds ($747 million) raised by British biotechs in the first quarter of the year has been hailed as a “sign ...

Eli Lilly’s run of near-weekly acquisitions still shows no sign of letting up, with the Big Pharma now buying Ajax ...

The promise of a better pan-RAS inhibitor Erasca has been described as the poor man’s Revolution Medicines. Impoverished ...

Three sectors are undergoing notable shifts in early 2026: B2B marketing is moving toward transparent, permission-based data strategies; UK biotech financing is rebounding despite a stagnant IPO ...

If you bought XBI a year ago and held it, you are up roughly 65%. If you bought Direxion Daily S&P Biotech Bull 3X Shares ...

Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce risk in a volatile sector.

Legend Biotech Corporation looks like a J&J acquisition target as Carvykti sales surge and Phase 2 data impress. Click for ...

A looming $300 billion patent cliff by 2030 is spurring a surge in biotech M&A, with March 2026 alone seeing $31.5 billion in deals. Analysts highlight CRISPR Therapeutics, Intellia Therapeutics, and ...

What did Eli Lilly see in a struggling biotech startup that made the pharma giant want to pay billions for it? Bryan Roberts ...

As part of this partnership, Mayo Clinic has made an equity investment in Sana Biotech, reflecting a shared goal of creating ...

If biotech funding continues to increase this year, Danaher could benefit.

By Lee Kwon-hyung and Yoon Min-sik Daejeon, long recognized as South Korea’s science capital, is moving to turn its research ...